BioAge Labs, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

Last price 5.94 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 272.63M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular e...